Oxford Nanopore Technologies, a UK-based developer of human genome technology, has raised £25m ($41m) from a consortium including its DNA sequencing marketing partner, Illumina UK.
The other investors in Oxford Nanopore, which is valued in the round at £155m, included hedge fund Lansdowne Partners, London-listed developer of intellectual property-based businesses IP Group, mutual fund manager Invesco Perpetual and venture capital firm Redmile Group.
IP Group said its 21.5% beneficial stake in Oxford Nanopore was valued at £33.4m after…
